natgillin/translations-raw huggingface dataset:
The process of claim 26, wherein the process gas heating is assisted with combustion of natural gas. The process of claim 26, wherein the process comprises drying the feedstock to remove at least a portion of moisture contained within the feedstock, and wherein heat produced from the process gas heating is utilized, at least in part, for the drying. 
zagrijavanje procesnim plinom barem dijela navedenih kondenziranih para s plinom koji sadrži kisik, korištenje zagrijavanja procesnim plinom, barem djelomično, za sušenje navedene sirovine radi uklanjanja barem dijela vlage sadržane unutar navedene sirovine, i korištenje zagrijavanja procesnim plinom, barem djelomično, za zagrijavanje navedenog uglavnom inertnog plina.
A system according to claim 12, wherein the refrigerant composition is as defined in claim 3, and wherein the system is a freezer operable at a box temperature of -17.8°C (0°F). 
Sustav prema zahtjevu 12, naznačen time da je rashladna tvar kako je definirana u zahtjevu 3, te pri čemu je sustav hladnjak koji radi na temperaturi od -17.8°C (0°F).
preferably in a patient previously treated with a chemotherapeutic drug or with radiotherapy, more preferably wherein the patient is at least partially resistant to the treatment with said chemotherapeutic drug or with radiotherapy, or 
Vežuća molekula koja se može vezati na L1, naznačena time što je namijenjena upotrebi u skladu s patentnim zahtjevom 4, kod pacijenta prethodno liječenog kemoterapijskom lijekom ili radioterapijom.
An isolated cell or a non-human organism transformed or transfected with a nucleic acid molecule of claim 8, wherein the cell is e.g. a prokaryotic cell or a eukaryotic cell, preferably a mammalian cell or more preferably a human cell. 
Stanica ili nehumani organizam transformiran ili transfektiran molekulom nukleinske kiseline iz zahtjeva 9, pri čemu je stanica primjerice prokariotska ili eukariotska stanica, poželjno stanica sisavca ili optimalno ljudska stanica.
The composition according to claim 1 wherein the GPR119 agonist has an EC50 of less than 10 µM. 
Uporaba u skladu sa zahtjevom 37, naznačena time, da GPR119 agonist ima EC50 manji od 10 uM.
The polypeptide of any one of claims 1 to 4, wherein the polypeptide is selected from the group consisting of SEQ ID: 2, (SEQ ID NO: 4, SEQ ID NO. 18, SEQ ID NO: 20 and a polypeptide that is 95% identical to any of SEQ ID: 2, SEQ ID NO: 4, SEQ ID NO. 18 or SEQ ID NO: 20. The polypeptide of any one claims 1 to 5, wherein the polypeptide is isolated. The polypeptide of any one of claims 1 to 6 for use in medicine. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu polipeptid ima najmanje 90%, poželjnije 95%, najpoželjnije 99% identičan slijed aminokiselinskom slijedu kako je navedeno u SEQ ID NO:4. Sastav iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu polipeptid ima slijed kako je navedeno u SEQ ID NO:2 ili SEQ ID NO:4. Sastav iz bilo kojeg od patentnih zahtjeva 1 do 6, nadalje sadrži adjuvans.
The formulation of claim 1, wherein the ingredient is a mixture of a hydrophilic solvent and a lipophilic solvent. 
Formulacija prema zahtjevu 1, naznačena time, da je sastojak mješavina hidrofilnog otapala 1 lipofilnog otapala.
storing the G-CSF composition obtained in step (b) in the frozen state; and 
(c) pohranjivanje G-CSF-sastava dobivenog u koraku (b) u zamrznutom stanju na vremenski period od najmanje mjesec dana; 1
A solid dosage form comprising (A) particles consisting of amorphous bardoxolone methyl admixed with (B) particles consisting of one or more hydrophilic binders, wherein said particles (A) constitute a therapeutically effective amount of bardoxolone methyl. 
PATENTNI ZAHTJEVI Čvrsti oblik doziranja koji sadrži (A) čestice koje se sastoje od amorfnog bardoksolon metila i staklaste pomoćne tvari, gdje je oblik doziranja naznačen time što ima jednu temperaturu staklenja, u smjesi s
A device according to claim 3, wherein the adjustment means (7a,7b) are connected to the axis of suspension (4b) of the upper rod (2a) of the knee lever closing mechanism (1). 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time što su sredstva za namještanje (7a, 7b) spojena na osovinu za vješanje (4b) gornje šipke (2a) koljenaste polugo mehanizma za zatvaranje (1).
Y is -(C3-C8)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, or the radical of the formula III, wherein 
Y je Â«(C:3-Cg)-cikloalkil, gdje cikloalkil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s RI, ili radikal formule III, gdje
The rock plate 14 may be an ordinary, flat plate or may be domed, as is shown in the figure. 
Ploča uz stijenu 14 može biti obična ravna ploča ili može biti kupolasta, kako je prikazano na slici.
DA2 expression or activity may be reduced in the identified plants as methods described above. A plant or progeny plant may be identified by i) measuring the amount of DA1, DA2 and/or EOD1 polypeptide in one or more cells of the plant ii) measuring the amount of DA1, DA2 and/or EOD1 mRNA in one or more cells of the plant or iii) sequencing the nucleic acid encoding the DA1, DA2 and/or EOD1 polypeptide in one or more cells of the plant and identifying the presence of one or more mutations. 
HR P20182197 T1 PATENTNI ZAHTJEVI Postupak povećavanja količine sjemena po jediničnoj površini, prirasta i/ili biomase biljke, naznačen time, da obuhvaća sljedeće: smanjivanje ekspresije ili aktivnosti polipeptida DA2 unutar stanica navedene biljke, pri čemu polipeptid DA2 obuhvaća RING-domenu od SEQ ID NO: 2, i biljka ima smanjenu ekspresiju ili aktivnost od DA1 ili smanjenu ekspresiju ili aktivnost od DA1 1EODI, dok se ekspresija ili aktivnost polipeptida DA2 smanjuje pomoću sljedećeg:
The combined product of claim 4, wherein the composition consists essentially of honey and L-alanyl-L-glutamine. 
Kombinirani proizvod za primjenu u skladu sa zahtjevom 6 ili zahtjevom 7, koji sadrži med i L-alanil-L-glutamin.
14–15 shows the packaging in a closed condition from the front and backside, respectively. 
Slike 14-15 prikazuju pakiranje u zatvorenom stanju s prednje strane odnosno sa stražnje strane.
This example illustrates a suitable therapeutic method for the compounds of this invention. 
Ovaj primjer ilustrira prikladnu terapeutsku metodu za spojeve iz izuma.
Genomics 70, 181-9 (2000). VEGF165 for use for treating a motoneuron disease wherein said VEGF165 is continuously administered for up to at least 4 weeks at the place of onset at a dose range between 0.01 µg/kg/day and 0.6 µg/kg/day. 
L Čimbenik rasta vaskularnog endotela VEGF165 za uporabu u liječenju bolesti motoneurona, naznačen time, da se rečeni VEGF 165 neprekidno primjenjuje i to najmanje 4 tjedna od početka uzimanja u dozi u omjeru između 0.01 tt/kg/day and 0.6 Pe/kg/dan.
A process according to claim 20, followed by conversion of the cyanide into the corresponding thioamide and, optionally, further conversion of said thioamide into isavuconazole, when the phenyl moiety of said thioamide is a 2,5-difluoro-substituted, or ravuconazol, when the phenyl moiety of said thioamide is a 2,4-difluoro-substituted, via reaction with an alpha-keto-substituted 4-cyanoacetophenone reagent. 
21.Postupak prema zahtjevu 20, naznačen time da zatim slijedi pretvorba cijanida u odgovarajući tioamid, te proizvoljno, daljnja pretvorba navedenog tioamida u isavukonazol, kada je fenilni dio navedenog tioamida 2,5-difluor-supstituiran, ili ravukonazol, kada je fenilni dio navedenog tioamida 2,4-difluor-supstituiran, putem reakcije s alfa-keto-supstituiranim 4-cijanoacetofenon reagensom.
carbobenzyloxy protection of a compound of formula 1: 
(1) karbobenziloksi zaštita spoja formule 1: 20
The presence of atmospheric oxygen is also necessary for the curing. 
Za otvrdnjavanje je također nužna i prisutnost atmosferskog kisika.
Composition according to claim 9, characterised in that said plasticizers are selected from among triethyl citrate, polyethylene glycol, polypropylene glycol, glycerol monostearate, polyols, glycerine, vegetable oils and/or a mixture thereof. 
Pripravak u skladu s patentnim zahtjevom 9, naznačen time što se navedeni plastifikatori biraju između trietilcitrata, polietilen-glikola, polipropilen-glikola, glicerol-monostearata, poliola, glicerola, biljnih ulja i/ili njihove smjese.
Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. 
Alternativno, arilmetilna skupina poput benzilne skupine može biti uklonjena, na primjer, hidrogenacijom na katalizatoru poput paladija-na-ugljiku.
The method of claim 1, further comprising an adhesive agent. The method of claim 16, wherein the adhesive agent is selected from the group consisting of sucrose aluminum sulfate complex, chitosan and derivatives thereof, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, cross-linked or uncross-linked polyacrylates, cross-linked polyacrylates, acidic cross-linked or uncross-linked polyacrylates, polyacrylic acid homopolymers or copolymers, aminoalkyl methacrylate copolymers, methacrylic acid/methylmethacrylate copolymer, alkylacrylate/alkylmethacrylate copolymers, ammoniomethacrylate copolymers, carbomer homopolymers or copolymers, hydrophilic polysaccharide gums, maltodextrins, cross-linked alginate gums, polycarboxylated vinyl polymers, pectins, xanthan gums, alginic acid, modified alginic acids, and combinations thereof. 
Tableta za oralno disperziranje sukladno bilo kojem od zahtjeva 1-3, koja nadalje sadrži adheziv, pri čemu je adheziv odabran iz skupine koju čine saharoza aluminijevog sulfata kompleksa, kitozana i njegovih derivata, polivinilpirolidona, metilceluloze, natrij karboksimetil celuloae, hidroksipropil celuloza, umreženih ili neumreženih poliakrilata, umreženi poliarilata, kiselih umreženi ili neumreženi poliakrilat, homopolimer ili kopolimer poliakrilne kiseline, aminoalkil metakrilatnih kopolimer, kopolimer metakrilne kiseline/metilmetakrilat, kopolimer alkilakrilat/alkitmetakrilat, amoniometakrilatnih kopolimer, karbomernih homopolimer ili kopolimer, hidrofilne polisaharidne gume, maltodekstrin, gelov umrežene alginatne gume, polikarboksilirane vinilne polimere, pektina, ksantanske gume, alginske kiseline, modificirane alginske kiseline ili njihovih kombinacija.
A process for preparing an influenza virus antigen, comprising the steps of: (i) growing influenza virus in a cell culture system, in the absence of egg-derived materials and of antibiotics; (ii) inactivating the influenza viruses grown in step (i), in the absence of formaldehyde; and (iii) preparing a vaccine antigen formulation from the inactivated influenza viruses. 
Postupak za dobivanje sterilne formulacije antigena virusa influence koja ne sadrži konzervanse sa živom, ne sadrži antibiotik, ne sadrži formaldehid 1 materijale dobivene od jaja, naznačen time da sadrži slijedeće korake: (i) uzgajanje virusa influence u sustavu stanične kulture, bez prisutnosti materijala dobivenih od jaja i antibiotika; (11) inaktiviranje virusa influence uzgojenih u koraku (i), bez prisutnosti formaldehida; te (iii) dobivanja formulacije antigena cjepiva iz inaktiviranih virusa influence, bez prisutnosti timerosala.
A kit comprising 1 to 11 dosage units intended for a treatment period of 12 weeks formulated in a form for transdermal delivery of Gestodene, said dosage unit comprises a composition for transdermal delivery comprising a drug-containing layer that comprises Gestodene and a carrier selected from the group consisting of polyisobutylenes, polybutenes, polyisoprenes, polystyrenes, styrene isoprene styrene block polymers, styrene butadiene styrene block polymers and mixtures thereof, wherein the drug-containing layer has a solubility for said Gestodene of no more than 3% by weight of the drug-containing layer, and wherein the Gestodene is present in an amount ranging between 0.5 and 3% by weight of the drug-containing layer. 
PATENTNI ZAHTJEVI Komplet koji sadrži 1 do 11 jediničnih doza namijenjen za razdoblje liječenja od 12 tjedana koji je formuliran u obliku za transdermalno davanje Gestodena, te navedena jedinica doziranja sadrži pripravak za transdermalno davanje koji sadrži sloj koji sadrži lijek koji uključuje Gestoden i nosač koji je odabran iz skupine koja sadrži poliizobutilene, polibutene, poliizoprene, polistirene, stiren izopren stiren blok polimere, stiren butadien stiren blok polimere i njihove smjese, naznačen time da sloj koji sadrži lijek ima topljivost za navedeni Gestoden od ne više od 3% težinski sloja koji sadrži lijek, te pri čemu je Gestoden prisutan u količini u rasponu između 0.5 i 3% težinski sloja koji sadrži lijek.
The immunoconjugate of claim 1 wherein the engineered targeting antibody comprises a heavy chain having SEQ ID NO: 1 and a light chain having SEQ ID NO: 2. 
Imunokonjugat u skladu s patentnim zahtjevom 1, naznačen time što konstruirano ciljano protutijelo sadrži teški lanac koji ima SEQ ID NO: 1 i laki lanac koji ima SEQ ID NO: 2.
is NHR14, where R14 is selected from the group consisting of: 
R gdje Y*' se bira iz skupine koju čine:
This type of assay generally requires a radiolabelled ligand to the RUP25 receptor. 
Taj tip ispitivanja općenito traži radiološki označen ligand za RUP25 receptor.
improving circulating glucose levels, glucose tolerance and/or circulating cholesterol levels, lowering circulating LDL levels, and/or increasing HDULDL ratio in an individual in need thereof; or 
(b) poboljšanje razina glukoze u cirkulaciji, tolerancije na glukozu i/ili cirkulacijskih razina kolesterola, snižavanje cirkulacijskih razina LDL, i/ili povećanje omjera HDL/LDL, kod pojedinca kojemu je to potrebno; ili
Valve (10) according to claim 15 or 16, wherein said valve body (12) externally has a plurality of centring elements (12a), radially projecting from said valve body (12) . 
Ventil (10) u skladu s patentnim zahtjevom 15 1li 16, pri čemu navedeno tijelo ventila (12) izvana ima više elemenata za centriranje (124), koji se pružaju radijalno iz navedenog tijela ventila (12).
The T cell according to any one of claims 1-3, wherein the antigen is selected from the group consisting of prostate-specific membrane antigen (PSMA), Carcinoembryonic Antigen (CEA), IL13R alpha, her-2, CD19, NY-ESO-1, HIV-1 Gag, Lewis Y, Mart-1, gp100, tyrosinase, WT-1, hTERT, and mesothelin. 
'T-stanica prema bilo kojem od zahtjeva 1 do 14, naznačena time da je antigen odabran iz skupine koju čine membranski antigen specifičan za prostatu (PSMA), karcinoembrijski antigen (CEA), IL13R alfa, her-2, CD19, NY-ESO-I, HIV-I Gag, Lewis Y, Mart-1, gp100, tirozinaza, WT-1, hTERT, i mezotelin.
The injection nozzle according to at least one of claims 1 to 6, further comprising a finger or tongue (28) disposed and protruding from the second end (14). 
Mlaznica za injektiranje prema barem jednom od zahtjeva 1 do 6, naznačena time da je nastavak ili jezičac (28) konstruiran
is Glu, is Ile, is an amino acid residue having a side chain with a functionalized —NH2 group, wherein the functionalized —NH2 side chain group is functionalized by —C(O)—R5, wherein R5 is a moiety comprising up to 100 carbon atoms and optionally heteroatoms independently selected from halogen, N, O, S and P, 
predstavlja aminokiselinski ostatak koji ima bočni lanac sa skupinom -NH2, pri čemu je -NH2 skupina bočnog lanca funkcionalizirana s -C(O)-R5, pri čemu R5 može biti dio koji sadrži do 50 ili do 100 ugljikovih atoma i proizvoljno heteroatome odabrane od halogena, N, O, S i/ili P,
A compound of formula I shown below: 
Spoj prema dolje prikazanoj formuli I: e
an inner phase which is a solid dispersion comprising COMPOUND A, a hydrophilic binder, a surfactant and 
A), hidrofilno vezivo, surfaktant i vanjsku fazu koja sadrži sredstvo za zakiseljavanje, punilo, te lubrikant.
The forming method according to claim 4, wherein: the outer case has inner walls, constituting a second part of the shaped walls of the forming chamber which forms the outer shape of the socket to be formed; 
- - vanjsko kućište (12) ima unutrašnje stjenke (120), koje čine drugi dio oblikovanih stijenki (11) komore za oblikovanje (1) koje formiraju vanjski oblik čahure koja se oblikuje;
The inventor suggests that the nucleus pulposus in the disc space of an intervertebral disc may transform to solid and dense connective tissue, similar to the connective tissue of the annulus fibrosus, when a composition for use in the treatment of intervertebral disc-related pain according to the present invention is administered into the nucleus pulposus. 
HR P20191633 T1 PATENTNI ZAHTJEVI Kompozicija za uporabu u liječenju boli povezane s intervertebralnim diskom, naznačena time što navedena kompozicija sadrži mliječnu kiselinu ili njenu farmaceutski prihvatljivu sol, pri čemu se navedena kompozicija primjenjuje u prostor diska koji sadrži nucleus pulposus intervertebralnog diska.
The compound according to claim 1 which is vortioxetine (DL)-pyroglutamate monohydrate in crystalline form with XRPD reflections at 6.16, 9.25, 17.68 and 18.12 (°2θ) (±0.1 °2θ). 
Spoj prema patentnom zahtjevu 1, naznačen time što je vortioksetin (DL)-piroglutamat monohidrat u kristalnom obliku s XRPD refleksijama kod 6,16, 9,25, 17,68 i 18,12 (220) (+0,1 220).
the capsule is provided with sealing material at its outer surface, which sealing material is geometrically arranged in order to be exposed to the fluid pressure in the capsule enclosure space, and 
- < ječahura (1) snabdjevena na svojoj vanjskoj površini s materijalom za brtvljenje (8), koji materijal za brtvljenje (8) je geometrijski raspoređen tako da bude izložen fluidu koji je pod tlakom u prostoru u kojemu jo obuhvaćena čahura, i pri čemu su
The method according to claim 16 wherein the array of lenses(11, 12; 17, 18) is formed by imprinting of the second layer (8). 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se polje leća (11,12;17,18) načini utiskivanjem sloja (8) od plastičnog materijala.
operating said speed controller such that said drive speed is above a lower drive speed limit, that has a non-zero value, while drilling a borehole by said borehole equipment, wherein said lower drive speed limit is determined from: 
- upravljanje (37) navedenim kontrolorom brzine (20) tako da je brzina pogona iznad niže granice brzine prilikom bušenja navedenom opremom za bušotine (10), pri čemu se niža granica brzine izvodi 1z:
at least one second transportation belt for transferring the dough sheet that exits the second kneading device into one at least one funnel device and onto at least one third transportation belt; 
najmanje jednu drugu transportnu traku za prijenos izlazećeg tijesta iz drugog uređaja (2) za miješanje u najmanje jedan kalup (3) za oblikovanje tijesta u listove i na najmanje jednu treću transportnu traku,
characterized in that trifluoromethanesulphonic anhydride is reacted with 2,2,3,3-tetrafluoro-1-propanol without solvent and the resulting 2,2,3,3-tetrafluoropropyl trifluoromethanesulphonate is reacted with a compound of the formula (XIIa) 
' naznačen time da trifluormetansulfonski anhidrid reagira sa 2,2,3,3-tetrafluor-1-propanolom bez otapala i nastali 2,2,3,3-tetrafluorpropil trifluormetansulfonat reagira sa spojem s formulom (XIIa) m pe H
The method of item 12, wherein said administration is to be repeated at least two, three, four, five, six, seven, eight, nine of ten times, after determination of a MRD negative status. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što navedenu primjenu treba ponoviti najmanje dva, tri, četiri, pet, šest, sedam, osam, devet ili deset puta, nakon što se odredi status negativnosti na MRD.
Omeprazole (3.0 g, 0.0087 mol) was added to a solution of LiOH (0.207 g, 0.00865 mol) in deionized water and then methylene chloride (25 ml) was added. 
Omeprazol (3,0 g, 0,0087 mola) je dodan u otopinu LiOH (0,207 g, 0,00865 mola) u deioniziranoj vodi i tada je dodan metilen klorid (25 ml).
This tearing of the foil member 5 can e.g. occur as soon as the pressure inside the capsule exceeds a threshold value. 
Ovo trganje elementa od folije 5 može se, na primjer, pojaviti čim tlak unutar čahure pređe vrijednost praga.
Composition according to claim 19, wherein the aldehyde-releasing compound is selected from the group consisting of formaldehyde-releasing biocides, acetaldehyde-releasing biocides, succinaldehyde-releasing biocides, 2-propenal-releasing biocides and mixtures thereof. 
Sastav u skladu s patentnim zahtjevom 18, pri čemu je spoj koji otpušta aldehid odabran iz grupe koja se sastoji od biocida koji otpuštaju formaldehid, biocida koji otpuštaju acetaldehid, biocida koji otpuštaju sukcinaldehid, biocida koji otpuštaju 2-propenal i njihovih smjesa.
wherein the intracellular portion of the rodent CD47 polypeptide is encoded by the exons downstream of exon 7 of a rodent CD47 gene; and wherein the humanized CD47 gene is operably linked to a rodent CD47 promoter. The rodent of claim 1, wherein the humanized CD47 gene is formed from a replacement of a genomic fragment comprising exons 2-7 of an endogenous rodent CD47 gene at an endogenous rodent CD47 locus, with a genomic fragment comprising exons 2-7 of the human CD47 gene. 
HR P20190634 T1 PATENTNI ZAHTJEVI no Glodavac čiji genom sadrži humanizirani gen CD47, naznačen time što humanizirani gen CD47 sadrži egzon 1 iz endogenog glodavačkog gena CD47, egzone 2-7 iz ljudskog gena CD47, te egzone nizvodno od egzona 7 iz endogenog glodavačkog gena CD47, gdje je humanizirani gen CD47 operabilno spojen s promotorom endogenog glodavčkog CD47.
Item 6. The pharmaceutical preparation according to Item 5 which is used as a vasodilator, hypotensive drug, aquaretic agent, or platelet aggregation inhibitor. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time, da se koristi kao vazodilator, hipotenzijski lijek, akvaretičko sredstvo ili inhibitor agregacije pločastih stanica.
The composition of claim 1, the compound represented by a structure of Formula 7 or stereoisomer thereof or pharmaceutically acceptable salt thereof: 
Sastav iz patentnog zahtjeva 1, tvar sadrži strukturu Formule 7 ili njen stereoizomer ili njenu farmaceutski s prihvatljivu sol.
A preform as claimed in Claim 1, characterised in that the thickness (g1) of the flange (3) is less than or equal to the thickness (g2) of the cylindrical neck (2). 
Predoblik prema Zahtjevu 1, naznačen time što je debljina (gl) oboda (3) manja od ili jednaka debljini (g2) cilindričnog vrata (2).
said detachable tube (7) winding around a winder (10) located outside of the tube to be filled, and the catalyst particles being contained in: 
- navedena odvojiva cijev (7) namotana je oko namotaja (10) postavljenog izvan cijevi koja se puni, a čestice katalizatora su sadržane u:
According to an aspect of the invention, the stereo image consist of more than two images. 
Identifikacijski dokument (1) prema bilo kojem od prethodnih zahtjeva, gdje se fantomska slika (D) sastoji od više od dvije slike.
setting a merge candidate on the merge list specified by a merge index as motion information of a current prediction unit; generating a prediction block of the current prediction unit using the motion information; and generating a reconstructed block using the prediction block and the residual block, 
postavljanje informacija o pokretu iz kandidata bloka za spajanje na listu za spajanje koja odgovara indeksu za spajanje kao informaciji o pokretu iz tekuće predikcijske jedinice; generiranje predikcijskog bloka za tekuću predikcijsku jedinicu korištenjem informacija o pokretu; i generiranje kvantiziranog bloka inverznim skeniranjem komponenti kvantiziranog koeficijenta, generiranjem transformiranog bloka inverznom kvantizacijom kvantiziranog bloka primjenom parametra kvantizacije i generiranje rezidualnog bloka inverznom transformacijom transformiranog bloka;